INNOVA CAPTAB LIMITED Fair Value
INNOVACAP · Healthcare · Current price ₹1,071
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹201 | 14% ROE fading to 13% over ~10 yrs, on ₹191 book |
| Relative P/E | ₹963 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹325 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹1,116 | Street consensus 12-month target price |
Is INNOVA CAPTAB LIMITED undervalued?
DocStoX estimates the fair value of INNOVA CAPTAB LIMITED at ₹557 per share, versus the current market price of ₹1,071. That puts the stock about -48.0% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹201), Relative P/E (₹963), Graham floor (₹325), Analyst target (₹1,116). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹201 (bear) to ₹557 (base) to ₹1,116 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on INNOVA CAPTAB LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.